ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout - Fierce Biotech

As reported by FierceBiotech

Kelonia Therapeutics has shared the largest slice of data yet for its in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid to buy the Boston biotech. | Kelonia Therapeutics has shared the largest slice of data yet for an i…

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on FierceBiotech ↗

Market Samachar is a news aggregator. This article was originally published by FierceBiotech. Tap the button above to read the full story on their site.

INDIAN SpaceX reserves up to 5% of IPO stock for staff and friends Markets-Economic Times
INDIAN AI giant Anthropic confidentially files for US IPO Markets-Economic Times
COMPANIES Ahead of Market: 10 things that will decide stock market action on Tuesday Stocks-Markets-Economic Times
COMPANIES Market Trading Guide: NMDC among two stock recommendations for Tuesday Stocks-Markets-Economic Times
COMPANIES JetBlue flags higher fuel costs as Iran conflict drags on Stocks-Markets-Economic Times
COMPANIES Ola Electric launches QIP to raise funds, sets floor price at Rs 37.74 a share Stocks-Markets-Economic Times
COMPANIES EasyJet says possible US bid 'highly opportunistic' as shares jump 10% Stocks-Markets-Economic Times
INDIAN Aluminium hits four-year high on renewed Middle East supply risks Markets-Economic Times

ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout - Fierce Biotech

More from Market Samachar